Werewolf Therapeutics
Tracked across 1 events · 6 articles · First seen Aug 21, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Werewolf Therapeutics and Ambros Therapeutics announced a definitive all-stock merger agreement to create a combined company focused on advancing neridronate, Ambros' late-stage treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1). The combined company will…
Impact: Werewolf Therapeutics is the acquiring entity in the all-stock merger, with its stock surging over 100% on the announcement. The deal implies a relatively low valuation of $47.5 million, and pre-merger stockholders will own only about 6.8% of the combined company.
Aug 21, 2026 · 6 articles
100
Werewolf Therapeutics entered merger agreement Ambros TherapeuticsWerewolf Therapeutics Ambros Merger
90
Werewolf Therapeutics secured private placementWerewolf Therapeutics Ambros Merger
ERGEN INTELLIGENCE
Track Werewolf Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard